EcoDrugPlus


Synonyms	Kolliphor p 188 Kolliphor p188 Lutrol f 68 Lutrol f68 MST-188 Pluracare f 68 Pluronic f-68 Pluronic f68 Pluronic f68lf Poloxalkol Poloxamer 188 Poloxamer 188lf Poloxamer-188 Polykol Vepoloxamer
Status
Molecule Category	UNKNOWN
UNII	LQA7B6G8JG

Synonyms

Kolliphor p 188

Kolliphor p188

Lutrol f 68

Lutrol f68

MST-188

Pluracare f 68

Pluronic f-68

Pluronic f68

Pluronic f68lf

Poloxalkol

Poloxamer 188

Poloxamer 188lf

Poloxamer-188

Polykol

Vepoloxamer

Status

Molecule Category

UNKNOWN

UNII

LQA7B6G8JG


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Resources	Reference
ChEMBL	CHEMBL3137355
FDA SRS	LQA7B6G8JG

Resources

Reference

ChEMBL

CHEMBL3137355

FDA SRS

LQA7B6G8JG


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

VEPOLOXAMER

Cross References